BioLineRx (NASDAQ:BLRX) Earns “Hold” Rating from Jones Trading

BioLineRx (NASDAQ:BLRX)‘s stock had its “hold” rating reiterated by research analysts at Jones Trading in a note issued to investors on Wednesday, MarketBeat reports.

A number of other research firms also recently commented on BLRX. HC Wainwright increased their target price on shares of BioLineRx from $9.00 to $26.00 and gave the company a “buy” rating in a research report on Monday. StockNews.com downgraded shares of BioLineRx from a “hold” rating to a “sell” rating in a research report on Tuesday, March 18th.

BioLineRx Trading Down 5.2 %

Shares of BLRX stock opened at $2.94 on Wednesday. The company has a debt-to-equity ratio of 2.11, a quick ratio of 1.37 and a current ratio of 1.52. The company has a 50 day moving average price of $3.44 and a 200 day moving average price of $10.51. The stock has a market capitalization of $9.79 million, a P/E ratio of -0.33 and a beta of 1.39. BioLineRx has a fifty-two week low of $2.85 and a fifty-two week high of $35.60.

Institutional Trading of BioLineRx

An institutional investor recently bought a new position in BioLineRx stock. Highbridge Capital Management LLC bought a new position in shares of BioLineRx Ltd. (NASDAQ:BLRX) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 1,010,012 shares of the biotechnology company’s stock, valued at approximately $215,000. Highbridge Capital Management LLC owned approximately 50.50% of BioLineRx at the end of the most recent quarter. Institutional investors and hedge funds own 1.56% of the company’s stock.

About BioLineRx

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.